Nepal | November 26, 2020

Next crop of COVID-19 vaccine developers take more traditional route

Reuters
Share Now:

CHICAGO/BERLIN: The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs.

The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop.

Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed.

They include messenger RNA (mRNA) technology used by Moderna Inc and Pfizer Inc with partner BioNTech SE , and inactivated cold virus platforms used by Oxford University/AstraZeneca Plc, Johnson & Johnson and CanSino Biologics, whose vaccine has been approved for military use in China.

Merck & Co in September started testing a COVID-19 vaccine based on a weakened measles virus that delivers genes from the new coronavirus into the body to stimulate an immune response to the coronavirus.

Of these, only the technology offered by J&J and CanSino that use cold viruses as vectors to deliver coronavirus genetic material have ever produced a licensed vaccine – for Ebola.

The next set of candidates – with late-stage trial results expected in the first half of 2021 – are heavily skewed toward approaches that have produced successful vaccines.

Conventional methods include using a killed or inactivated version of the pathogen that causes a disease to provoke an immune response, such as those used to make flu, polio and rabies vaccines.

Also more common are protein-based vaccines that use purified pieces of the virus to spur an immune response. Vaccines against whooping cough, or pertussis, and shingles employ this approach.

French drugmaker Sanofi is developing a protein-based COVID-19 vaccine employing the same approach it uses for its Flublok seasonal flu vaccine. Sanofi expects to start the final phase of testing in early December, with approval targeted in the first half of 2021.

While Novavax Inc has not yet produced a licensed vaccine, it is using similar purified protein technology and expects to start a late-stage US trial involving 30,000 volunteers in late November.

“Those are more traditional approaches, so we can feel more comfortable that we have a lot of experience with them,” said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia.

Offit also sees promise in some of the inactivated virus vaccines being developed by Chinese researchers, including Sinopharm’s China National Biotec Group (CNBG), one of the few first-crop developers using a traditional technique.

Other second-wave developers are making vaccines based on virus-like particles (VLPs), which mimic the structure of the coronavirus but contain no genetic material from it.

VLP vaccines can be produced in a variety of different types of cells, including mammal, bacterial, insect, yeast and plant cells. This approach has been used to develop vaccines for hepatitis B and human papillomavirus.

Quebec’s Medicago is testing a VLP COVID-19 vaccine grown in tobacco plants with the backing of tobacco company Philip Morris .

Medicago has yet to produce an approved vaccine, but has completed large-scale testing for a seasonal flu vaccine using this approach. It plans to begin mid-stage trials of its COVID-19 vaccine next month and aims to make up to 1 billion doses a year by 2023.

Others are looking at alternative delivery methods, such as the nasal spray vaccine being developed by a team at Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise, which is based on a modified flu virus.

CHALLENGES AHEAD

The second crop, however, could face problems completing large studies if the current leaders bring their vaccines over the finish line in the coming months.

“If we get a super vaccine in December, from company x, which is on the market, it will be difficult to recruit participants into other studies,” said Peter Kremsner from the University Hospital in Tuebingen, Germany.

“Then everyone will say, if the vaccine exists, I will get vaccinated now with this vaccine. This will definitely prove a problem for recruitment,” added Kremsner, who is testing CureVac’s mRNA COVID-19 vaccine in early clinical trials with backing from the Bill & Melinda Gates Foundation.

On the flip side, it is easier and faster to prove efficacy when community spread of the virus is rampant as is happening again in the United States, Europe and elsewhere, a potential advantage for companies starting large-scale vaccine trials in the near future.


Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

Argentina soccer legend Maradona dies of heart attack

BUENOS AIRES, Nov 25  - Argentina soccer legend Diego Maradona, widely regarded as one of the game's greatest ever players, died of a heart attack on Wednesday, his lawyer said. Maradona, 60, had recently battled health issues and underwent emergency surgery for a subdural haematoma several week Read More...

Real leave Inter close to exit after Vidal sees red

MILAN: Real Madrid claimed a first-ever win at San Siro on Wednesday, beating Inter 2-0 in the Champions League after the Serie A side had midfielder Arturo Vidal sent off for dissent in the first half. Eden Hazard converted a seventh-minute penalty and Achraf Hakimi deflected Rodrygo's Read More...

MoFAGA

New procedure for self-evaluation issued

KATHMANDU, NOVEMBER 25 The Ministry of Federal Affairs and General Administration has issued the ‘Local Level Institutional Capacity Self-evaluation Procedure-2020’ to identify strengths and weaknesses of local bodies by assessing their work procedures and achievements for the purpose of maki Read More...

Act now to address shadow pandemic of VAW, says WHO

KATHMANDU, NOVEMBER 25 Urgent action is needed across the WHO South-East Asia Region to strengthen efforts to protect women and girls from violence and to support their health needs amid the ongoing COVID-19 pandemic, said the World Health Organisation Regional Office for South-East Asia today. Read More...

Be sensitive towards protecting rights of violence survivors: PM

KATHMANDU, NOVEMBER 25 Prime Minister KP Sharma Oli stated that the government would not tolerate any sort of gender-based discrimination and violence. In a message released on the occasion of 16 Days of Activism against Gender-based Violence, PM Oli reaffirmed the government’s efforts to op Read More...

Foden strike sends City into Champions League knockouts

ATHENS: Manchester City midfielder Phil Foden finished off a brilliant team move as his side saw off Olympiakos Piraeus 1-0 away from home on Wednesday to book their place in the Champions League's last 16. After dominating possession with little reward, City found a breakthrough in Read More...

Ensure right to life: NHRC

KATHMANDU, NOVEMBER 25 The National Human Rights Commission has drawn the government’s attention to the need to protect people’s right to life. The human rights watchdog’s statement comes in the wake of recent protest in Bardibas of Mahottari, where police firing claimed the life of Budd Read More...

Indian foreign secretary Harsh Vardhan Shringla to arrive today

KATHMANDU: Foreign Secretary of India Harsh Vardhan Shringla will land in Nepal today for a two-day official visit. Shringla's visit follows a series of Indian high-level visits to Nepal made in an attempt to better the once very strained relations between the two countries following the May-bord Read More...